Correlation Between Aprea Therapeutics and HCW Biologics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Aprea Therapeutics and HCW Biologics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Aprea Therapeutics and HCW Biologics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Aprea Therapeutics and HCW Biologics, you can compare the effects of market volatilities on Aprea Therapeutics and HCW Biologics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Aprea Therapeutics with a short position of HCW Biologics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Aprea Therapeutics and HCW Biologics.

Diversification Opportunities for Aprea Therapeutics and HCW Biologics

0.85
  Correlation Coefficient

Very poor diversification

The 3 months correlation between Aprea and HCW is 0.85. Overlapping area represents the amount of risk that can be diversified away by holding Aprea Therapeutics and HCW Biologics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on HCW Biologics and Aprea Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Aprea Therapeutics are associated (or correlated) with HCW Biologics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of HCW Biologics has no effect on the direction of Aprea Therapeutics i.e., Aprea Therapeutics and HCW Biologics go up and down completely randomly.

Pair Corralation between Aprea Therapeutics and HCW Biologics

Given the investment horizon of 90 days Aprea Therapeutics is expected to under-perform the HCW Biologics. But the stock apears to be less risky and, when comparing its historical volatility, Aprea Therapeutics is 2.86 times less risky than HCW Biologics. The stock trades about -0.19 of its potential returns per unit of risk. The HCW Biologics is currently generating about -0.03 of returns per unit of risk over similar time horizon. If you would invest  332.00  in HCW Biologics on September 11, 2025 and sell it today you would lose (138.50) from holding HCW Biologics or give up 41.72% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthStrong
Accuracy100.0%
ValuesDaily Returns

Aprea Therapeutics  vs.  HCW Biologics

 Performance 
       Timeline  
Aprea Therapeutics 

Risk-Adjusted Performance

Weakest

 
Weak
 
Strong
Over the last 90 days Aprea Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of conflicting performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in January 2026. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.
HCW Biologics 

Risk-Adjusted Performance

Weakest

 
Weak
 
Strong
Over the last 90 days HCW Biologics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in January 2026. The current disturbance may also be a sign of long term up-swing for the company investors.

Aprea Therapeutics and HCW Biologics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Aprea Therapeutics and HCW Biologics

The main advantage of trading using opposite Aprea Therapeutics and HCW Biologics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Aprea Therapeutics position performs unexpectedly, HCW Biologics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in HCW Biologics will offset losses from the drop in HCW Biologics' long position.
The idea behind Aprea Therapeutics and HCW Biologics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.

Other Complementary Tools

Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.